Maze Therapeutics Inc

We are in a Stage 2 advancing environment with a strong Lockout Rally driving upside urgency. The medium-term directional asymmetry remains bullish supported by the advancing Market Stage and continuation pattern. Short-term price is extended and overbought and is pulling back into rising EMAs, making immediate buy conditions unfavorable. We will defer entry and watch for a pullback to absorb into the 9/21/50 EMA support zone before engaging.

• ↑Phase 2 HORIZON trial delivered 36% mean uACR reduction (>30% POC)
• ↑$362.9 M cash funds operations into 2029
• ↓Earnings yield negative at –2.6%, reflecting ongoing losses